Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28615852 | 1.00 | TLR2 (0.55) | TLR2MDM2PTPN1MMEECE1 | |
| SCHEMBL12476097 | 1.00 | TLR2 (0.55) | TLR2MDM2PTPN1MMEECE1 | |
| SCHEMBL18683448 | 1.00 | TLR2 (0.55) | TLR2MDM2PTPN1MMEECE1 | |
| SCHEMBL23253745 | 0.94 | TLR2 (0.52) | TLR2MDM2PTPN1MDM4TP53 | |
| SCHEMBL27041569 | 0.91 | TLR2 (0.49) | TLR2MDM2PTPN1MDM4TP53 | |
| SCHEMBL27041543 | 0.91 | TLR2 (0.49) | TLR2MDM2PTPN1MDM4TP53 | |
| SCHEMBL1000115 | 0.91 | TLR2 (0.62) | TLR2MDM2MDM4TP53 | |
| SCHEMBL1044856 | 0.91 | TLR2 (0.62) | TLR2MDM2MDM4TP53 | |
| SCHEMBL29398487 | 0.91 | TLR2 (0.62) | TLR2MDM2MDM4TP53 | |
| SCHEMBL29382791 | 0.91 | TLR2 (0.62) | TLR2MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3147367-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| CN-106117310-A | Small molecule conjugates for Intracellular delivery bioactive compound | 弗·哈夫曼-拉罗切有限公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-2658981-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| CN-103282502-B | small molecule conjugates for intracellular delivery of biologically active compounds | 弗·哈夫曼-拉罗切有限公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2658982-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-9301990-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| CN-103282503-B | Small molecule conjugates for intracellular delivery of nucleic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-02 | — | — | CN | disclosed |
| US-9198947-B2 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| CN-104328121-A | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN LA ROCHE | 2015-02-04 | — | — | CN | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2658981-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| EP-2658982-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| CN-103282503-A | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN LA ROCHE | 2013-09-04 | — | — | CN | disclosed |
| CN-103282502-A | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN LA ROCHE | 2013-09-04 | — | — | CN | disclosed |
| WO-2012089602-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012089352-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | SNRPE, PHAX, SNRPA | TLR2 3166/4885MDM2 1070/4885PTPN1 3856/4885 |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | SNRPE, PHAX, SNRPA | TLR2 2499/4885MDM2 741/4885PTPN1 3985/4885 |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | SNRPE, PHAX, SNRPA | TLR2 3166/4885MDM2 1070/4885PTPN1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.